Recent Company News

• 05:41 PM ET Jun 08, 2026
  

  DBV Technologies to present data from VITESSE study and preview recently initiated THRIVE study at EAACI Congress 2026 (€2.84, 0.00)

• 07:45 PM ET Jun 02, 2026
  

  DBV Technologies screens first participant in THRIVE Phase 2 study of VIASKIN Peanut patch in infants with peanut allergy (€3.05, 0.00)

• 09:39 AM ET May 19, 2026
  

  Transcript Intelligence: DBV Technologies at H.C. Wainwright BioConnect Investor Conference

• 03:41 PM ET May 15, 2026
  

  Duquesne discloses changes in holdings in 13F filing

• 04:30 PM ET Apr 30, 2026
  

  DBV Technologies reports Q1 GAAP EPS ($0.11) vs year-ago ($0.26) - 10-Q (€3.63, 0.00)

• 06:40 AM ET Apr 16, 2026
  

  StreetAccount Summary - European unusual volume traders

• 11:11 AM ET Apr 02, 2026
  

  StreetAccount Summary - US unusual volume traders

• 05:12 PM ET Mar 26, 2026
  

  DBV Technologies reports FY EPS ($1.05) vs FactSet ($1.31) [8 est, ($2.80)-(0.40)]; provides cash position & outlook, anticipated FY26 milestones (€3.53, 0.00)

• 05:52 AM ET Mar 25, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 05:40 PM ET Mar 24, 2026
  

  DBV Technologies joins CAC Mid 60 and SBF 120 indices, effective 23-Mar (€3.35, 0.00)